LEADER 01045nam0 22002651i 450 001 UON00027840 005 20231205102047.108 100 $a20020107d1972 |0itac50 ba 101 $aeng 102 $aIN 105 $a|||| 1|||| 200 1 $aIslamic Influence on Indian Society$fM. Mujeeb 210 $aMeerut$cMeenakshi prakashan$d1972 xv$d204 p. ; 21 cm 606 $aINDIA$xSTORIA ISLAMICA$3UONC002328$2FI 606 $aINDIA$xSTORIA SOCIALE$xISLAM$3UONC008660$2FI 620 $dMeerut$3UONL000524 686 $aSI IV B$cSUBCONT. INDIANO - STORIA MODERNA (1526-1947)$2A 700 1$aMUJEEB$bM.$3UONV012910$0641140 712 $aMinakshi Prakashana$3UONV247147$4650 801 $aIT$bSOL$c20240220$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00027840 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI SI IV B 302 $eSI SA 33748 5 302 996 $aIslamic Influence on Indian Society$91188493 997 $aUNIOR LEADER 04734nam 2201057z- 450 001 9910557116703321 005 20210501 035 $a(CKB)5400000000040879 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68688 035 $a(oapen)doab68688 035 $a(EXLCZ)995400000000040879 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCytobiology of Human Prostate Cancer Cells and Its Clinical Applications 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (184 p.) 311 08$a3-03936-034-5 311 08$a3-03936-035-3 330 $aThe number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most patients with early-stage PCa can be treated with appropriate therapy, such as radical prostatectomy or irradiation. On the other hand, androgen deprivation therapy (ADT) is the standard systemic therapy given to patients with advanced PCa. ADT induces temporary remission, but the majority of patients (approximately 60%) eventually progress to castration-resistant prostate cancer (CRPC), which is associated with a high mortality rate. Generally, well-differentiated PCa cells are androgen dependent, i.e., androgen receptor (AR) signalling regulates cell cycle and differentiation. The loss of AR signalling after ADT triggers androgen-independent outgrowth, generating poorly differentiated, uncontrollable PCa cells. Once PCa cells lose their sensitivity to ADT, effective therapies are limited. In the last few years, however, several new options for the treatment of CRPC have been approved, e.g., the CYP17 inhibitor, the AR antagonist, and the taxane. Despite this progress in the development of new drugs, there is a high medical need for optimizing the sequence and combination of approved drugs. Thus, the identification of predictive biomarkers may help in the context of personalized medicine to guide treatment decisions, improve clinical outcomes, and prevent unnecessary side effects. In this Special Issue Book, we focused on the cytobiology of human PCa cells and its clinical applications to develop a major step towards personalized medicine matched to the individual needs of patients with early-stage and advanced PCa and CRPC. We hope that this Special Issue Book attracts the attention of readers with expertise and interest in the cytobiology of PCa cells. 606 $aMedicine$2bicssc 610 $aabiraterone 610 $aAKR1C3 610 $aandrogen deprivation therapy 610 $aandrogen receptor 610 $aandrogen receptor dependency 610 $aandrogen sensitivity 610 $aanimal model 610 $aapoptosis 610 $aautophagy 610 $acabazitaxel 610 $aCAF 610 $acastration resistant prostate cancer 610 $acastration-resistant prostate cancer 610 $aCaveolin-1 610 $aCCL2 610 $aCCL22 610 $aCCL5 610 $achemotherapy 610 $aCW069 610 $acytokine 610 $adiet 610 $adocetaxel 610 $adocetaxel resistance 610 $aenzalutamide 610 $aEPI-002 610 $aepigenetics 610 $afat 610 $afibroblast 610 $afibroblast growth factor 610 $afibroblast growth factor receptor 610 $afibroblast-dependent androgen receptor activation 610 $afibroblasts 610 $aG1 cell cycle arrest 610 $ahigh-fat diet 610 $ahormone-nai?ve prostate cancer 610 $aimmune cells 610 $aimmunohistochemistry 610 $ain vitro 610 $ain vivo 610 $ainflammation 610 $aKIFC1 610 $aLSD1 610 $amigration 610 $amouse 610 $an/a 610 $aobesity 610 $aP-glycoprotein 610 $apirfenidone 610 $aprostate cancer 610 $aprostate-specific antigen 610 $aradiotherapy 610 $aresistance 610 $asplice variant 610 $atestosterone 610 $aTGF?1 610 $atime to PSA nadir 610 $atissue microarray 610 $aTP53-regulated inhibitor of apoptosis 1 610 $atumour microenvironment 610 $atumour stroma 615 7$aMedicine 700 $aIshii$b Kenichiro$4edt$01299430 702 $aIshii$b Kenichiro$4oth 906 $aBOOK 912 $a9910557116703321 996 $aCytobiology of Human Prostate Cancer Cells and Its Clinical Applications$93025151 997 $aUNINA